Head-to-Head Comparison
Doximity vs Epocrates: Which Is Better for Physicians?
Doximity: The Professional Medical Network with AI-Powered Tools Epocrates: Drug Reference, Interaction Checker & Clinical Decision Support
Updated
Direct Answer
Source: Clinical AI Report, 2026
Key takeaways
- Doximity Ask gives cited AI answers in Instant or Thinking modes, while Epocrates has no natural-language search or AI clinical reasoning.
- Epocrates covers drug monographs, a multi-drug interaction checker and pill identification for free, and Epocrates Plus adds disease content and lab references for $179.99 a year (October 2026).
- Doximity’s 3,200+ drug monographs arrived with the August 2025 Pathway Medical acquisition and are still maturing, while Epocrates has focused on drug reference since 1998.
- Epocrates lists 600+ medical calculators for point-of-care checks, while Doximity adds Doximity Scribe, secure messaging, telehealth and digital fax.
Feature Comparison
| Feature | Doximity | Epocrates |
|---|---|---|
| Rating | Doximity: Good | Epocrates: Fair |
| Category | Doximity: Medical Professional Network & AI Tools | Epocrates: Drug Reference & Clinical Decision Support |
| Pricing | Doximity: Free (Ad-Supported) | Epocrates: Free (Basic) / $179.99/year (Plus) |
| Founded | Doximity: 2010 | Epocrates: 1998 |
| Headquarters | Doximity: San Francisco, CA | Epocrates: San Mateo, CA |
| Evidence Citations | Doximity: Yes | Epocrates: No |
| AI Differential Diagnosis | Doximity: Yes | Epocrates: No |
| Drug Database | Doximity: Yes | Epocrates: Yes |
| Drug Interaction Checker | Doximity: No | Epocrates: Yes |
| Medical Calculators | Doximity: No | Epocrates: Yes |
| Natural Language Search | Doximity: Yes | Epocrates: No |
| Document & Image Upload | Doximity: Yes | Epocrates: No |
| EHR Integration | Doximity: No | Epocrates: No |
| Mobile App | Doximity: Yes | Epocrates: Yes |
| Built-in Dialer | Doximity: Yes | Epocrates: No |
| AI Clinical Scribe | Doximity: Yes | Epocrates: No |
| CME Credits | Doximity: Yes | Epocrates: No |
| Multi-Language | Doximity: No | Epocrates: No |
Strengths & Limitations
Doximity
Strengths
- +Largest physician network in the US (3M+ members, ~85% of US physicians)
- +Ask is advertised as free for U.S. healthcare professionals; confirm account eligibility
- +Pathway Medical acquisition adds 3,200+ peer-reviewed drug monographs
- +PeerCheck physician review program (10,000+ medical experts, co-chaired by Eric Topol)
- +Evidence-based clinical answers grounded in structured medical literature
- +300,000+ clinicians actively using AI tools (Q3 FY2026)
- +AI Scribe for ambient clinical documentation
- +Secure HIPAA-compliant messaging and integrated telehealth
- +100+ health system enterprise deployments
Limitations
- –AI revenue not yet commercialized — long-term AI business model unproven
- –Networking-heavy interface can be distracting for clinical use
- –Pathway integration is recent (late 2025) — clinical depth still maturing
- –Company-published preference study lacks independent peer review
- –Revenue model relies on pharmaceutical and health system advertising
- –Check current Ask availability and workflow fit for your device and institution
Epocrates
Strengths
- +Free tier with genuinely useful drug interaction checker and monographs
- +Fast, well-designed mobile app optimized for point-of-care use
- +Over 1 million active healthcare professional users
- +Includes a pill identification tool
- +Affordable Plus tier at $179.99/year compared to competitors
- +Long track record since 1998 with consistent reliability
Limitations
- –No AI-powered differential diagnosis or clinical reasoning
- –Disease content lacks depth compared to UpToDate or DynaMed
- –No natural-language query support or evidence synthesis
- –Limited EHR integration for individual users
- –Plus tier content updates can lag behind newer platforms
Key Statistics
Doximity
Epocrates
Citable Summaries
Doximity
Doximity has an editorial score of 70/100 (3.5/5), calculated from Clinical AI Report's published criteria weights. It ranks #4 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
Epocrates
Epocrates has an editorial score of 63/100 (3.2/5), calculated from Clinical AI Report's published criteria weights. It ranks #6 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
Our Assessment
In our 2026 evaluation, Doximity (ranked #4, 3.5 stars) outperforms Epocrates (ranked #6, 3.2 stars) in overall physician satisfaction and editorial scoring. Doximity is best suited for physicians already embedded in the Doximity ecosystem who want AI-powered clinical answers, drug reference, and documentation without switching platforms. Especially relevant for practices with enterprise Doximity contracts. Meanwhile, Epocrates is a stronger choice for physicians and residents seeking a fast, reliable, mobile-first drug reference tool with a strong free tier — especially for interaction checks and dosing at the point of care. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.